Shots:

• NICE has issued final draft guidance recommending Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of IPF in adults with an FVC
• Additionally, the clinical trial results showed that patients treated with nintedanib achieved a slow decline of lung function over PBIO in IPF patients with an FVC above 80%, which suggested that the effect of nintedanib is maintained over time while the median survival from diagnosis is 2-5yrs.
• Nintedanib marks the first therapy to be recommended by NICE that can be administered by taking one or two capsules, BID

Ref: NICE  | Image: Boehringer Ingelheim